---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-338013"
form_type: "8-K"
ticker: "RLAY"
cik: "0001812364"
company_name: "Relay Therapeutics, Inc."
filed_at: "2026-08-06T20:11:08+00:00"
generated_at: "2026-08-06T20:15:07.076658+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Relay Therapeutics Q2 2026 net loss $83.7M; cash $910.9M; selected zovegalisib triplet for 1L breast cancer

## Summary
- Net loss $83.7M ($0.41/sh) vs $70.4M ($0.41/sh) in Q2 2025; R&D expenses rose to $76.5M.
- Cash $910.9M at June 30, 2026, up from $642.1M at March 31, 2026, after $316M follow-on offering in May 2026.
- Selected zovegalisib + atirmociclib + endocrine therapy as 1L breast cancer triplet; Phase 3 trial expected early 2027.
- Initial ReInspire data: 60% volumetric response at 12 weeks in vascular anomalies; expansion cohorts opened.
- ATM offering capacity increased to $462.978M; $162.978M already sold under prior $250M program.

## SEC filing metadata
- accession: 0001193125-26-338013
- form_type: 8-K
- ticker: RLAY
- cik: 0001812364
- company_name: Relay Therapeutics, Inc.
- filed_at: 2026-08-06T20:11:08+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812364/000119312526338013/0001193125-26-338013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812364/000119312526338013/rlay-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-338013
- JSON: https://secwatch.observer/filing/0001193125-26-338013.json
- Plain text: https://secwatch.observer/filing/0001193125-26-338013.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.